autism research - new med re plasticity

[Guest guest]

Cellceutix Autism Research Demonstrates Increase In Serotonin Levels In Three

Areas Of The Brain

Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have

completed another study in the research of KM-391, their novel compound being

developed to treat the core symptoms of autism. Cellceutix is pioneering

research in autism treatments and has been making solid progress with

pre-clinical research as announced in previous press releases.

Neonatal serotonin depletion and decreased brain plasticity are established

observations in the autistic brain. The Cellceutix team has identified a

reliable animal model and has been successful in chemically inducing these

characteristics in the model. The data collected to this point has been

promising as KM-391 has shown to be successful in altering the serotonin and

brain plasticity levels resulting in physical and behavioral changes in the

model that are similar to the " non-autistic " control groups.

The latest research involved physical measurements of serotonin levels in the

cerebral cortex, hippocampus, and caudate nucleus areas of the brain. Several

groups of rats were established with two of the groups being injected to induce

the symptoms of autism. After 48 days, the brains were assayed for serotonin by

ELISA with the data showing that the administration of KM-391 significantly

increased serotonin levels in all 3 regions of the brain: cerebral cortex,

hippocampus, and caudate nucleus, from very low levels as observed with the

induced autism to normal levels as observed in placebo treated control which

received no treatment.

, Cellceutix Chief Executive Officer, commented, " This new data is

highly relevant as it reinforces the data from previous studies and further

solidifies our contention that serotonin levels in multiple brain regions may be

a necessary key to the next generation of autism treatments. "

Source:

Cellceutix Corporation